Cogent Biosciences' 15-min chart shows RSI Overbought, KDJ Death Cross.

Cogent Biosciences's 15-minute chart has triggered a warning signal, as the Relative Strength Index (RSI) has reached overbought levels, and the KDJ (KST-Diff) indicator has crossed below the zero line at 08/13/2025 12:30. This suggests that the stock price has increased too rapidly and may be unsupported by underlying fundamentals, indicating a shift in momentum towards the downside and potentially leading to further decreases in stock price.

Cogent Biosciences (NASDAQ: COGT) has recently triggered bearish signals in its 15-minute chart, raising concerns among investors. On August 13, 2025, at 12:30, the Relative Strength Index (RSI) reached overbought levels, while the KDJ (KST-Diff) indicator crossed below the zero line. These indicators suggest that the stock price has increased too rapidly and may not be supported by underlying fundamentals, signaling a potential shift in momentum towards the downside.

The RSI, a momentum oscillator, measures the speed and change of price movements of an asset. When the RSI exceeds 70, it indicates that the asset may be overvalued, and a price correction could be imminent. Similarly, the KDJ indicator, which is part of the KST (Kawase Technical Oscillator), suggests that the stock is losing momentum and could potentially reverse direction.

These signals come amidst a period of mixed analyst sentiment. While several analysts have raised their price targets for Cogent Biosciences, others have maintained more cautious stances. For instance, JPMorgan Chase & Co. recently increased its target price to $30.00, while Needham & Company LLC and Leerink Partners have also raised their targets. However, Wedbush and Robert W. Baird have maintained neutral ratings, indicating a more cautious outlook [1].

Technical indicators aside, Cogent Biosciences reported a quarterly adjusted loss of 53 cents per share for the quarter ended June 30, 2025, which was higher than the same quarter last year. Despite the financial setback, the stock has shown significant growth, rising by 67.8% this quarter and gaining 54.5% so far this year. The company's lead product candidate, bezuclastinib (CGT9486), has been the focus of its development efforts, targeting genetically defined diseases [2].

Investors should remain vigilant and consider the broader market context when interpreting these signals. While the technical indicators suggest a potential downturn, the company's earnings performance and growth prospects should also be closely monitored.

References:
[1] https://www.marketbeat.com/instant-alerts/jpmorgan-chase-co-increases-cogent-biosciences-nasdaqcogt-price-target-to-3000-2025-08-07/
[2] https://www.ainvest.com/news/cogent-biosciences-15min-chart-triggers-macd-death-cross-kdj-death-cross-bearish-marubozu-2508/